Efficacy and mechanisms of Ci-Gu-Tang against pancreatic cancer:a study using patient-derived modelsOA
Pancreatic cancer(PC)is a highly lethal disease,and current clinical drugs often have significant side effects.Traditional Chinese medicines,particularly food and medicine homology herbs,present novel opportunities for the development of low-toxicity tumor treatments.It is imperative to further explore the application of these substances in the field of tumor therapy.To investigate the effect of Ci-Gu-Tang(CGT)on PC both in vitro and in vivo and to elucidate its underlying mechanism.In this study,liquid chromatography-mass spectrometry(LC-MS)technology was utilized to validate the constituents of CGT,whereas network pharmacology was employed to further analyze the 37 active ingredients in CGT and their nine targets associated with PC.Protein-protein interaction(PPI)investigations revealed that the three potential key targets are epidermal growth factor receptor(EGFR),AKT serine/threonine kinase 1(AKT1),and signal transducer and activator of transcription 3(STAT3).Molecular docking was used to elucidate the binding mode and energy between four active ingredients(β-sitosterol,stigmasterol,quercetin,and prangenidin)and the above three targets.Subsequent in vitro and in vivo studies further validated its anti-PC efficacy and confirmed the involvement of the EGFR/AKT1/STAT3 signaling pathway.The utilization of patient-derived organoid(PDO)and patient-derived xenograft(PDX)models enhanced the clinical significance of this investigation.The present research utilized network pharmacology,molecular docking,LC-MS,and in vitro and in vivo experiments to examine the effects and mechanism of CGT in the treatment of PC.This study revealed thatβ-sitosterol,stigmasterol,quercetin,and prangenidin could be practical components by inhibiting tumorigenesis through the EGFR/AKT1/STAT3 axis.PDO and PDX models also demonstrated the effectiveness of CGT.This study represents a pioneering effort in the use of patient-derived models to investigate the potential of food and medicine homology species in cancer treatment.
Jiatong Li;Ao Gu;Nannan Tang;Mengyao Li;Yingbin Liu
State Key Laboratory of Systems Medicine for Cancer,Shanghai Cancer Institute,Renji Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200127,China Department of Biliary-Pancreatic Surgery,Renji Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200127,ChinaState Key Laboratory of Systems Medicine for Cancer,Shanghai Cancer Institute,Renji Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200127,ChinaState Key Laboratory of Systems Medicine for Cancer,Shanghai Cancer Institute,Renji Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200127,China Department of Biliary-Pancreatic Surgery,Renji Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200127,ChinaState Key Laboratory of Systems Medicine for Cancer,Shanghai Cancer Institute,Renji Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200127,China Department of Biliary-Pancreatic Surgery,Renji Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200127,ChinaState Key Laboratory of Systems Medicine for Cancer,Shanghai Cancer Institute,Renji Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200127,China Department of Biliary-Pancreatic Surgery,Renji Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200127,China
医药卫生
Ci-Gu-tangPancreatic cancerFood and medicine homologyPatient-derived organoidsPatient-derived xenograftsEGFr/aKt1/Stat3 signaling pathway
《Journal of Future Foods》 2026 (6)
P.1129-1144,16
supported by the National Natural Science Foundation of China(91940305)。
评论